(Reuters) - CHICAGO, July 2 - Medtronic Inc. on
Monday said its Endeavor drug-eluting stent compared favorably
to Boston Scientific Corp.'s Taxus stent in a key
study, bringing the product a step closer to market.
The data, from Medtronic's "Endeavor IV" clinical trial,
will be used to support the device maker's application to the
U.S. Food and Drug Administration to sell the Endeavor stent in
the United States.
Read more at Reuters.com Government Filings News
Monday said its Endeavor drug-eluting stent compared favorably
to Boston Scientific Corp.'s Taxus stent in a key
study, bringing the product a step closer to market.
The data, from Medtronic's "Endeavor IV" clinical trial,
will be used to support the device maker's application to the
U.S. Food and Drug Administration to sell the Endeavor stent in
the United States.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment